Tag: Amgen

Amgen Completed $13.4bn Deal to Acquire Worldwide Rights to Otezla

amgen
Amgen announced that it completed its $13.4-billion deal to acquire worldwide rights to the psoriasis drug Otezla (apremilast) from Celgene. As a result, it now anticipates full-year sales ranging fro...

Amgen Entered into Strategic Collaboration with BeiGene

amgen
Amgen announced that it has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest ph...

Amgen Will Offer Repatha® at Lower List Price Option from 2020

Amgen announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high cholesterol and cardiovascular disease proven to reduce heart attacks and strokes, w...

FDA Approved Amgen’s sBLA for Nplate®

Amgen announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribin...

UCB and Amgen EVENITY® Received Positive CHMP Opinion

UCB and Amgen announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion reco...

Amgen Announced Positive Results from Two Clinical Trials Phase 3 BLINCYTO®

Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free ...

U.S. District Court Rules in Favor of Sanofi and Regeneron in Praluent® Patent Litigation

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen’s asserted patent claims for...

Amgen to Acquire Rights for Otezla® for $13.4bn

amgen
Amgen announced that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire worldwide rights to Otezl...

Amgen and Allergan Announced Positive Results from Clinical Study of Rituxan®

research
Amgen and Allergan plc. announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to...

US District Court Upheld Validity of Two Patents Covering Amgen’s Enbrel

patents
A US district court upheld the validity of two patents covering Amgen's Enbrel (etanercept) in response to a lawsuit the company filed against Novartis' Sandoz unit over the latter's biosimilar Erelzi...

Amgen and Novartis to Stop Alzheimer’s Prevention Study

Amgen, Novartis and Banner Alzheimer's Institute have announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the...

Amgen and Allergan Introduce Two Biosimilars in the U.S.

molecule
Amgen and Allergan announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTI™ (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in th...

Amgen Update on Status of EVENITY™ in the EU

Amgen and UCB announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Mar...

Amgen and the Institute for Protein Design Announce Partnership

Amgen and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, an...

Amgen, Merck, Eli Lilly Sue the U.S. Government to Block Rule Requiring Drug Prices in TV Ads

Three pharmaceutical companies sued the federal government to block a proposal requiring drug manufacturers include the list price of prescription drugs in television ads, the latest volley by the ind...

BLINCYTO Five-Year Overall Survival Data Presented by Amgen

Amgen announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive a...